一项系统综述与荟萃分析:评估每3个月一次GnRHa在绝经前乳腺癌卵巢功能抑制中的疗效与安全性
参考文献:
[1] Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-263.
[2] Francis PA, et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med. 2018;379(2):122-137.
[3] de Liz CD, et al. Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2026;217:48.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
文章原文
内容来自 医学界,版权归原作者所有。
阅读原文 ↗